Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425944 | 0.84 | GAA (0.46) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL2526731 | 0.82 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2002844 | 0.82 | ERN1 (0.47) | ERN1CD274PDCD1SLC9A1 | |
| SCHEMBL31119318 | 0.78 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2447300 | 0.78 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5597852 | 0.77 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15997561 | 0.76 | FFAR4 (0.49) | ERN1LRRK2SYKFFAR4NR3C1 | |
| SCHEMBL5109971 | 0.75 | S1PR1 (0.47) | ERN1CD274LRRK2SYKFFAR4 | |
| SCHEMBL2009285 | 0.74 | NR3C1 (0.52) | NR3C1PGR | |
| SCHEMBL8940603 | 0.74 | ERN1 (0.51) | ERN1LRRK2NR3C1PGRSLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | ERN1 1147/4885CD274 3460/4885LRRK2 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.